Journal article
Real-world effectiveness of chemoimmunotherapy and novel therapies for patients with relapsed/refractory aggressive large B-cell lymphoma
Clinical lymphoma, myeloma and leukemia, Vol.25(4), pp.e183-e199.e8
04/2025
DOI: 10.1016/j.clml.2024.11.014
PMID: 39966020
Abstract
: Clinical trials provide meaningful data regarding the safety and efficacy of novel therapies but there is often a lag between the time of new drug approval and information on post-treatment clinical outcomes in real-world practice. This study evaluated clinical outcomes in a large real-world population of patients with relapsed and/or refractory large B-cell lymphoma (r/r LBCL) treated with chemoimmunotherapy or novel therapies in second or later lines of therapy (2L+).
: Data from the Lymphoma Epidemiology of Outcomes (LEO) Consortium of Real-World Evidence (CReWE) cohort (1/1/2015–2/15/2023) were analyzed. Patients’ demographic and clinical characteristics were described and response rates, duration of response, progression-free survival, and overall survival were evaluated. Multivariable Cox proportional hazards regression models were used to assess associations between patient clinical characteristics and outcomes.
: The 2L+ cohort included patients treated with chemoimmunotherapy (N=593), lenalidomide-based therapy (n=60), polatuzumab vedotin-based therapy (N=116), tafasitamab-based therapy (N=55), and loncastuximab tesirine (N=42). Most patients with prior chimeric antigen receptor T-cell therapy (CAR-T) were refractory to the treatments. Overall response rates were low (<50%, with only one-quarter achieving complete response) and median duration of response and overall survival were short (<6 and <10 months, respectively) among patients treated with chemoimmunotherapy or novel therapies. The prognosis was worse for patients who had previously received CAR-T. Primary refractory status, high-risk disease, and failing 3 or more lines of therapy were significantly associated with worse outcomes.
: Patients with r/r LBCL have unfavorable outcomes and need more effective treatment alternatives.
MICROABSTRACT
This study examined the effectiveness of chemoimmunotherapy and novel therapies in patients (N=866) with relapsed and/or refractory large B-cell lymphoma (r/r LBCL) treated in real-world practice settings. Patients derived limited clinical benefit from the treatments; those with high-risk disease, primary refractory status, and more prior lines of therapy had especially poor outcomes. More treatment options are needed for r/r LBCL.
Details
- Title: Subtitle
- Real-world effectiveness of chemoimmunotherapy and novel therapies for patients with relapsed/refractory aggressive large B-cell lymphoma
- Creators
- Loretta J. Nastoupil - The University of Texas MD Anderson Cancer CenterClark R. Andersen - The University of Texas MD Anderson Cancer CenterAmy Ayers - The University of Texas MD Anderson Cancer CenterYucai Wang - Mayo ClinicThomas M. Habermann - Mayo ClinicDai Chihara - The University of Texas MD Anderson Cancer CenterBrad S. Kahl - Washington University in St. Louis School of MedicineBrian K. Link - University of IowaJean L. Koff - Emory UniversityJonathon B. Cohen - Emory UniversityPeter Martin - Weill Cornell MedicineIzidore S. Lossos - University of Miami Health SystemMichele Stanchina - University of Miami Health SystemSara Haddadi - University of MiamiCarla Casulo - University of Rochester Medical CenterSabarish Ayyappan - University of IowaRuitao Lin - The University of Texas MD Anderson Cancer CenterZiyi Li - The University of Texas MD Anderson Cancer CenterMelissa A. Larson - Mayo ClinicMatthew J. Maurer - Mayo ClinicLynn Huynh - Analysis GroupChi Gao - Analysis GroupRamya Ramasubramanian - Analysis GroupMei Sheng Duh - Analysis GroupAlex Mutebi - GenmabTongsheng Wang - GenmabMonika Jun - GenmabAnthony Wang - AbbVieRajesh Kamalakar - AbbVieAnupama Kalsekar - GenmabJames R. Cerhan - Mayo ClinicChristopher R. Flowers - The University of Texas MD Anderson Cancer Center
- Resource Type
- Journal article
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.25(4), pp.e183-e199.e8
- Publisher
- Elsevier Inc; DALLAS
- DOI
- 10.1016/j.clml.2024.11.014
- PMID
- 39966020
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Grant note
- Genmab
Editorial assistance was provided by Analysis Group, Inc., which provided paid consulting services to the study sponsor (Genmab) . This study was funded by Genmab.
- Language
- English
- Electronic publication date
- 12/2024
- Date published
- 04/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984770792302771
Metrics
7 Record Views